AVMA Cannabis Symposium - ONLINE
AVMA's Cannabis Symposium is the premier meeting for veterinary professionals and colleagues who want to understand the full scope of cannabis in veterinary medicine. This first-of-its-kind symposium will provide a 360-degree perspective on the topic.
As part of your AVMA Virtual Convention registration, join us for a dedicated CE track to explore cannabinoid pharmacology, see where clinical research is heading, and learn about veterinarians' regulatory obligations. Convention attendees will have access to all Virtual Convention CE sessions and events, including the cannabis symposium.
Thursday, August 20
Perspectives from a veterinary oncologist on potential clinical needs for cannabis-derived products
Hear from a practicing veterinary oncologist regarding the therapeutic areas of interest for cannabis-derived products, including contraindications, drug interactions, potential therapeutic needs, and more.
Cannabis toxicosis in veterinary companion animals
Drawing from the scientific literature and Pet Poison Helpline's case database, this lecture will focus on the real-world experiences associated with toxicosis due to CBD and/or THC product exposure in pets, including the expected (and unexpected) clinical signs, appropriate medical treatments, diagnostic tests, and prognosis.
Friday, August 21
FDA's regulation of cannabis products for animals
The presentation will cover the FDA's regulations related to food and drugs for animals containing cannabis and its components—including CBD—and the FDA's activities associated with the regulation of these products to date.
American Association of Veterinary State Boards (AAVSB) perspective on cannabis in veterinary medicine
Learn about the perspectives and policies of the veterinary medical boards on the use of cannabis in veterinary medicine, as well as the proposed direction for AAVSB model guidance to assist veterinary medical boards in informing licensees on the legal aspects of discussing and dispensing cannabis-derived products.
The importance of certified analytical testing and quality control (QC) in cannabis-derived products for safety and efficacy
This presentation will highlight issues regarding the uncertain chemical composition of cannabis-derived products that have not been evaluated for safety and efficacy. Learn what to look for in cannabis-derived products to ensure the safety of patients.
Saturday, August 22
Cannabis pharmacology and the endocannabinoid system
This brief overview will summarize what is currently known about the endocannabinoid system and identify potential targets through which the system might be manipulated therapeutically with exogenous cannabinoids. Pharmacokinetic considerations of phytocannabinoids will also be reviewed.
A glimpse into the pharmacokinetics of cannabinoids in dogs and cats with evidence of efficacy in canine osteoarthritis
Learn about recently published data of pharmacokinetic examinations of CBD-rich hemp in dogs and cats, as well as the results of three-month safety trials in dogs and cats using a similar CBD-rich hemp product with follow-up examination of the clinical efficacy in canine osteoarthritis.
Current research in clinical applications of cannabis-derived products
This presentation will review recent in vivo CBD research, including the pharmacokinetics of three delivery methods in dogs, the pharmacokinetics of concurrent administration of CBD and phenobarbital, a clinical trial pilot study investigating the therapeutic potential of CBD for the treatment of canine epilepsy, and the pharmacokinetics of escalating single doses of CBD in cats.